Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older
Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older
Active, not recruiting · NCT06904222 · Registry updated 2025-08-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older | Infections, Mononegavirales infectious disease, Paramyxoviridae infectious disease, Pneumovirus Infections, RNA Virus Infections, respiratory syncytial virus infectious disease, viral infectious disease | Active, not recruiting | Phase 1 | 2025-08-22 | NCT06904222 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Guangzhou Patronus Biotech Co., Ltd. | 7 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dangyang City Center for Disease Control and Prevention | Dangyang | China | 1 |